MedTrace Logo

Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat

NCT06371404 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-07-10

No results posted yet for this study

Summary

The overall objective of this study it to use Positron Emission Tomography (PET) brain imaging and a radiotracer that measures the epigenetic marker Histone Deacetylase 6 (HDAC6) to examine HDAC6 expression in people with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or concurrent PTSD and AUD with control groups. While there are a large number of studies conducted in preclinical stress and addiction models, these findings have not been translated to people living with these disorders. This study will examine relationships between HDAC6 and clinical variables of interest. Findings could direct treatment development.

Conditions

Interventions

DRUG

Bavarostat

Up to two injections of ≤ 5 mCi \[F18\] Bavarostat

Sponsors & Collaborators

  • Yale University

    lead OTHER

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-05
Primary Completion
2030-06-01
Completion
2031-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06371404 on ClinicalTrials.gov